ReviewJournal of neurovirology2026
Unmasking HAM/TSP: understanding HTLV-1-driven neurological disease.
Review in Journal of neurovirology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human T-cell Lymphotropic virus type 1 (HTLV-1) is a retrovirus that infected 10-20 million of individuals worldwide. HTLV-1 infection is associated with the development of various diseases, including HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia/lymphoma (ATLL). HAM/TSP is a chronic progressive neuroinflammatory disease characterized by motor impairment, spasticity, and other neurological manifestations. This narrative review provides a comprehensive overview of HAM/TSP following HTLV-1 infection. We discussed the virology and epidemiology of HTLV-1, transmission modes, and risk factors for infection. Furthermore, we delved into the pathogenesis of HAM/TSP disease, exploring the role of neuroimmunology and immune dysregulation. Viral proteins and host genetic factors that influence disease progression are also examined. Diagnostic approaches, including laboratory tests and imaging techniques, are discussed, along with available treatment options and immunomodulatory therapies. Additionally, we highlighted the history of HAM/TSP disease and provide insights into the global distribution and epidemiology. Finally, the current status and challenges of HTLV-1 vaccine development are addressed. This narrative review aims to enhance understanding of HAM/TSP disease following HTLV-1 infection, shedding light on key aspects of their etiology, diagnosis, and management, while emphasizing the need for continued research and public health interventions.
Indexed as
Identifiers
41714539What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.